ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
Browsing: Basic > Drug Development
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Could targeting neighboring bacterial populations help to combat bacterial vaginosis?’, as we ask the authors about the challenges in treating bacterial vaginosis (BV) and the future of this field.
Based on the demonstrated potential of laser-induced vapor nanobubbles to treat bacterial biofilm infections, we provide recommendations for future work in order to further mature this new technology into a promising anti-biofilm approach.
New research has suggested that a combination treatment of gentamicin with azithromycin was almost as effective as the currently used ceftriaxone for treating genital gonorrhea.
Take a look at this month’s industry headlines including news from ViiV Healthcare on long-acting and single dose formulations, sales for Eli Lilly and the possible development of a plague vaccine.
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
New research describes the use of small-molecule CD4 mimetic compounds that force HIV to undergo conformational changes, exposing normally hidden parts of the envelope and potential new targets.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.